Kornimate/medical-research-clean huggingface dataset:
prediction of long-term arm morbidity following breast cancer surgeries and treatments

Conditions: Breast Cancer

Summary: background: breast cancer (bc) treatments usually include a combination of surgery, chemotherapy and radiation. these life-saving treatments cause high percentages of arm morbidity, which often lasts for months, or develops months after surgery. arm and shoulder morbidity includes prolonged pain, restriction of movement, limitation of function and lymphedema (chronic progressive edema). all of these morbidities affect the quality of life (qol) of the recovering patients and require lengthy care. early detection of patients at risk and provision of proactive treatment can improve the recovery process from surgery and oncology treatments. aim: to develop a screening tool for the early identification of women at high risk for prolonged arm morbidity following bc treatments (persistent pain, lymphedema, function deficits and decreased range of motion), validate the tool, and examine the efficiency of intervention based on the the use of the tool.

the development and the assessment of the screening tool will conduct in three stages: 1. systematic review and meta-analysis to identify from the literature risk factors for lymphedema, prolong pain, decreased range of motion (rom), quality of life (qol) and function after breast cancer (bc) treatments and surgery. intended to understand which factor could be included in the screening tool. 2. development of the screening tool (study no. 1)- cross section study that will examine which of the risk factors found in the literature review/ meta-analysis will enter the tool. women up to 3 years after bc surgery will be evaluated for arm morbidity (pain, lymphedema, limitation of movement and limitation of function), and their association to the risk factors, using an online questionnaire. 3. a small cohort study (study no. 2)- aimed to validate the screening tool. the study will be conducted at the hospital's oncology institute, and will recruit bc survivors who come for routine follow-up six months till three years after surgery. patients will be asked to answer an online questionnaire, in addition, limb volume tests, strength and rom will be performed at the clinic. a comparison will be made between the physical parameters that indicate the morbidity of the arm and the score found in the screening tool. 4. a small prospective study (study no. 3)- the main goal of this study is to examine whether the use of the new questionnaire by the patients themselves will; a) affect the percentage of arrival to physical therapy (pt) treatments, b) will affect morbidity rates.

Eligibility criteria:
inclusion criteria: * patients aged 18-75 * independent * speaking hebrew and russian exclusion criteria: * patients who reported that from the time elapsed from the surgery they underwent additional surgery or an injury affecting the function/ pain of the arm. * patients suffering from advanced metastatic disease, or background diseases that limit function. * lymphedema prior to surgery.
looking for personalized nutrition for obesity/type 2 diabetes mellitus prevention

Conditions: Overweight and Obesity; Diabetes Mellitus, Type 2; Metabolic Syndrome; Genetic Predisposition; Diet Modification

Summary: the objectives of this trial are to assess the effects of interactions between genetic factors and diet with various macronutrient intake on the metabolic disorders, obesity and type 2 diabetes risk, prevention, development and progress.

this is a randomized, crossover study that includes 1 screening visit and four meal challenge test visits, separated by a 1-2-weeks washout period. the screening will include 2000 people, males and females, to evaluate the genotype frequencies in studied population, and to find carriers of the rare genetic single nucleotide polymorphisms (snps), who will fulfill all the other inclusion criteria. an oral glucose tolerance test (ogtt) will be completed at screening visit. moreover, the fasting blood samples will be collected for genetic analysis, and measurements of blood glucose and lipid metabolism profile, high-sensitivity c-reactive protein (hs-crp), hormones/peptides and other factors involved in energy balance regulation. subjects will be asked to record their daily food intake for 3 days. assessments of vital signs and body height and weight, waist and hip circumferences, body fat content and body fat distribution, review of concomitant medication/supplement use and inclusion and exclusion criteria, and evaluation of adverse effects will be performed throughout the study. to meal challenge test only men will be included, since the sex hormones may influence the study endpoints. subjects will be encouraged to maintain their habitual diet during wash-out periods. during the each meal challenge test subjects will consume one of the study meals in random order. the blood will be collected at fasting state and 30, 60, 120, 180 and 240 minutes after meal intake. the energy expenditure and substrate utilization will be measured by indirect calorimetry method at the fasting and postprandially.

Eligibility criteria:
inclusion criteria: * healthy men with normal body weight and with overweight/obesity * men with metabolic syndrome, hypertension, type 2 diabetes newly diagnosed, or not treated with any medicines * maintaining the usual diet and lifestyle throughout the study exclusion criteria: * infectious or acute diseases in the last 4 weeks before the study visits * any medicines/dietary supplements consumption in the last 4 weeks before the study visits * high level of daily physical activity * the following any special diet or dietary patterns (vegetarian, high-fat etc.) * the presence of any other significant disease which may affect the results (hormonal disorders, history of any surgeries on gastrointestinal tract, allergies known or suspected, heart failure, history of cancer, any kidney, pancrea and liver diseases, except non-alcoholic fatty liver) * abusive alcohol consumption * abusive coffee or energy drinks consumption * drug consumption
budd-chiari syndrome in china: balloon angioplasty alone or combined with stent placement?

Conditions: Budd-Chiari Syndrome

Summary: budd-chiari syndrome (bcs) is defined as the hepatic outflow obstruction from the small hepatic veins to the confluence between inferior vena cava and right atrium, which often leads to the life-threatening complications, such as liver failure and portal hypertension-related complications. at present, a stepwise treatment strategy is employed, including anticoagulation, thrombolysis, percutaneous recanalization (i.e., percutaneous transluminal angioplasty \[pta\] alone or in combination with stent placement), transjugular intrahepatic portosystemic shunt, and liver transplantation. in west, only less than 20% of bcs patients underwent percutaneous recanalization; by contrast, percutaneous recanalization is the most common treatment modality used in china. recently, an 11-year retrospective case series of 177 chinese patients with primary bcs has shown a higher rate of re-occlusion in the pta alone group than in the pta combined with stent placement group (31% versus 7.7%, p\<0.001). in addition, re-occlusion was regarded as the independent predictor of mortality. accordingly, we hypothesized that pta alone might have a worse survival than pta combined with stent placement in chinese patients with primary bcs.


Eligibility criteria:
inclusion criteria: 1. informed consent. 2. age 18-75 years old. 3. budd-chiari syndrome 4. child-pugh score \<13 points. 5. eligible for percutaneous recanalization. exclusion criteria: 1. pregnancy or lactation. 2. malignancy. 3. hiv infection. 4. severe cardiac or lung diseases. 5. severe renal dysfunction (serum\> 265.2 umol/l). 6. uncontrolled systemic infection. 7. allergic to contrast agents. 8. poor compliance. 9. a prior history of percutaneous recanalization. 10. ineligible for percutaneous recanalization. 11. liver cirrhosis with severe portal hypertension-related complications. 12. acute liver failure. 13. progressive deterioration of liver function.

Keywords: budd-chiari syndrome percutaneous recanalization treatment reocclusion patency
robot-aided assessment and rehabilitation of upper extremity function after stroke

Conditions: Stroke

Summary: the purpose of this clinical trial is to investigate the efficacy of a hybrid-based rehabilitation program for the upper extremity(ue) combining the interventions- functional electrical stimulation (fes) and robotic rehabilitation in individuals with chronic stroke. the main question it aims to answer is if the hybrid multi-muscle fes+robot upper extremity rehabilitation is more effective in improving the upper extremity motor impairments and function as compared to robotic upper extremity training alone.

individuals with chronic stroke(\> 6months after stroke) will be recruited. all participants will complete clinical and kinematic assessments at 2 time points(baseline and after 6 weeks training). each participant will receive 18 sessions of 60 minute upper extremity training over 6 weeks. study participants will be randomly assigned to receive either of the following upper extremity training- 1. hybrid multi-muscle fes+robot training group or 2.robot only training group. the following clinical assessments to measure the motor impairments and functional recovery will be performed: fugl-meyer upper extremity, modified ashworth scale, and wolf motor function test. kinematic assessments will be conducted using the reach robotic device and the kinereach/trakstar system. the following kinematic parameters will be collected: smoothness, range of motion, and speed.

Eligibility criteria:
inclusion criteria: 1. individuals with chronic stroke(\>6months post stroke) 2. age-22-85 years old 3. ability to perform a upper extremity forward reach of about 3 inches exclusion criteria: 1. upper extremity co-morbidities-pain, arthritis, and other neurological disorders 2. unable to tolerate electrical stimulation 3. have implants such as pacemaker, spinal cord or deep brain stimulator 4. have an elbow contracture of greater than 150 degrees 5. receiving botox injections within 3 months

Keywords: stroke rehabilitation robotic rehabilitation functional electrical stimulation
study of nmda antagonists and neuropathic pain

Conditions: Neuropathic Pain

Summary: the aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity. in clinical, after ketamine cure, clinicians have often difficulties to treat patients in order to maintain analgesia or suggest another treatment if analgesia induced by ketamine was not effective, which occurs in one quarter of patients. it will be very useful for monitoring of painful patients evaluate if memantine or dextromethorphan could be an effective therapeutic alternative in neuropathic pain treatment.

the aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity. in clinical, after ketamine cure, clinicians have often difficulties to treat patients in order to maintain analgesia or suggest another treatment if analgesia induced by ketamine was not effective, which occurs in one quarter of patients. it will be very useful for monitoring of painful patients evaluate if memantine or dextromethorphan could be an effective therapeutic alternative in neuropathic pain treatment.

Eligibility criteria:
inclusion criteria: * \> 18 years old * patient suffering chronic neuropathic pain * all chronic pain is retained except central or diabetic pain * answering patient at ketamine in pain treatment by investigator, and having already received ketamine * patient who completed before ketamine the following evaluation : dn4, qcd, qdsa, pgic questionnaires, had scale, leed's sleep evaluation and sf36. * patient who completed at the end of treatment the following evaluation : numerical scale and pgic * sufficient cooperation and understanding to comply to the requirements of study * acceptance to give a written concert * affiliation at system of french social security * inscription or acceptation of inscription at national register of voluntaries participant at research exclusion criteria: * against-indication at memantine or dextromethorphan administration : hypersensitivity at active substance or excipients, hypertension, antecedent cerebrovascular accident, severe cardiac insufficiency * patient with medical or surgical antecedents * patient with progressive disease at balance of inclusion * patient treated by an imao * woman in childbearing age not using effective contraceptive method, pregnant or lactating woman * patient who participated in another clinical trial, located in exclusion period or received benefits \> 4500 euros during 12 months before the beginning of trial * patient with cooperation and understanding insufficiency to comply to the requirements of protocol * patient with social protection * no affiliation at system of french social security

Keywords: nmda (n-methyl-d-aspartate) antagonists ketamine memantine dextromethorphan neuropathic pain
vaccine therapy in treating patients with non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells. purpose: phase i trial to study the effectiveness of vaccine therapy in treating patients who have non-small cell lung cancer.

objectives: * determine the safety and feasibility of immunization with autologous tumor lysate-pulsed dendritic cell vaccine in patients with non-small cell lung cancer. * determine the immunologic response in patients treated with this vaccine. outline: patients undergo surgery to remove all or most of the gross evidence of tumor. two months after surgery (or 4 months if chemotherapy and/or radiotherapy are required), patients undergo leukapheresis. peripheral blood mononuclear cells are isolated and cultured with interleukin-4 and sargramostim (gm-csf) to generate dendritic cells (dc). dc are then pulsed with tumor lysate prepared from previously removed tumor. patients receive autologous tumor lysate-pulsed dc vaccine subcutaneously twice, 4 weeks apart. patients are followed every 4 months for 2 years, every 6 months for 1 year, and then annually thereafter. projected accrual: a total of 10 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * diagnosis of operable stage ib, ii, or iiia non-small cell lung cancer * tumor diameter of at least 3 cm patient characteristics: age: * 18 to 75 performance status: * ecog 0-2 life expectancy: * at least 3 months hematopoietic: * wbc at least 3,000/mm\^3 * platelet count at least 100,000/mm\^3 hepatic: * bilirubin no greater than 2.0 mg/dl * ast less than 2 times upper limit of normal (uln) * lactate dehydrogenase less than 2 times uln * hepatitis b and c negative renal: * creatinine no greater than 1.4 mg/dl other: * positive cell mediated immunity test (i.e., greater than 5 mm induration in 48 hours with purified protein derivative (of tuberculin), candida, and mumps intradermal injection skin test) * hiv negative * no active systemic infection * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * at least 4 weeks since prior biological materials chemotherapy: * at least 4 weeks since prior cytotoxic or chemotherapeutic agents * concurrent chemotherapy allowed after surgery and before vaccination endocrine therapy: * no concurrent steroid therapy radiotherapy: * at least 4 weeks since prior radiotherapy * concurrent radiotherapy allowed after surgery and before vaccination surgery: * see disease characteristics

Keywords: stage i non-small cell lung cancer stage ii non-small cell lung cancer stage iiia non-small cell lung cancer
phase i azd2171 in patients with relapsed or refractory aml and elderly patients with denovo or secondary aml

Conditions: Leukaemia; Myelocytic; Acute

Summary: the study will be conducted across multiple european centres to assess the safety and tolerability of multiple doses of azd2171 in patients with aml.


Eligibility criteria:
inclusion criteria: * provision of written informed consent * male/female, 18 yrs or over * who performance status 0-2 * disease not responding to or relapsing after chemotherapy or elderly patients not suited to chemotherapy exclusion criteria: * acute myeloid leukaemia arising from previous chronic myeloid leukaemia or acute myeloid leukaemia of type fab m3 * previous treatment against new blood vessel formation (anti-angiogenic) * chest x-ray showing leukaemia in the lungs

Keywords: phase i aml de novo or secondary aml azd2171
metformin versus insulin in gestational diabetes

Conditions: Gestational Diabetes

Summary: gestational diabetes is traditionally treated with insulin. metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes. the investigators aim is to compare insulin and metformin in the treatment of gestational diabetes. the investigators hypothesis is that there is no difference between insulin and metformin treated mothers in the main outcome criteria (birth weight, neonatal complications).

gestational diabetes is traditionally treated with insulin. metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes. the investigators aim is to compare insulin and metformin in the treatment of gestational diabetes. the investigators hypothesis is that there is no difference between insulin and metformin treated mothers in the main outcome criteria (birth weight, neonatal complications). the study was performed as a randomized controlled trial in one center, turku university hospital using the non-inferiority design in june 2006 - december 2010. the final study population consisted of altogether 217 women, of whom 110 received metformin and 107 insulin.

Eligibility criteria:
inclusion criteria: * mothers with gestational diabetes who had at least twice plasma glucose at fasting \> 5.4 mmol/l and/or 1 hour postprandial value \> 7.7 mmol/l at 24 to 32 gestational weeks exclusion criteria: 1. fasting glucose \> 7.0 mmol/l or 1 hour postprandial plasma glucose \> 11.0 mmol/l or glycosylated hemoglobin a1c (hba1c) \> 7.0% 2. renal, hepatic or cardiac failure 3. pregestational use of metformin 4. pregnancy with multiple fetuses

Keywords: gestational diabetes metformin insulin
ct-guided radioactive iodine-125 seed implantation for recurrent desmoid tumors

Conditions: Brachytherapy; Desmoid Tumor; Radioactive Iodine-125 Seed Implantation

Summary: this study aimed to explore the long-term outcomes of ct-guided radioactive iodine-125 (i-125) seed implantation (risi) for recurrent desmoid tumor. a multicenter retrospective study reviewed 38 recurrent desmoid tumor patients receiving risi from july 2013 to july 2021.the clinical outcomes including overall response rate (orr), disease control rate (dcr), local control time (lct), overall survival (os), adverse events (aes), and symptom relief rate were statistically assessed.

desmoid tumor was characterized by a high potential of recurrence even following initial definitive treatment. there were considerable controversies regarding the management of recurrent desmoid tumor. this study aimed to explore the long-term outcomes of ct-guided radioactive iodine-125 (i-125) seed implantation (risi) for recurrent desmoid tumor. 38 patients, diagnosed with recurrent desmoid tumor, undergoing risi in 3 different centers including peking university third hospital, first affiliated hospital of the army medical university, and shengli oilfield central hospital from july 2013 to july 2021 were reviewed consecutively. the clinical outcomes including overall response rate (orr), disease control rate (dcr), local control time (lct), overall survival (os), adverse events (aes), and symptom relief rate were statistically assessed.

Eligibility criteria:
inclusion criteria: 1) recurrent desmoid tumor confirmed by pathologic or imaging diagnosis; 2) disease size ≥1 cm and ≤ 10 cm; 3) medically inoperable or individual refusal to resection; 4) karnofsky performance status (kps) ≥ 60; 5) adequate hematological reserves, hepatic function, renal function and heart function; 7) expected survival \> 3 months. exclusion criteria: 1) unconfirmed mass; 2) tumor invading the skin or mucous membrane; 2) patients with severe bleeding tendency; 3) patients with active infectious disease, trauma and severe wounds; 4) patients with any mental disorder; 5) patients with other somatic comorbidities of clinical concern; 6) pregnancy and lactation
"transradial ultra support technique" (trust)

Conditions: Coronary Arterioscleroses; Coronary Artery Disease

Summary: adequate support is required for challenging percutaneous coronary interventions (pci). the "transradial ultra support technique" (trust technique) is a new support technique that provides active support by deep pass of the coronary wire into the heart cavities (left ventricle-lv, right ventricle-rv) or aorta.


Eligibility criteria:
inclusion criteria: * subjects singed informed consent form * subjects eligible for percutaneous coronary intervention exclusion criteria: * age \ 75 years * subject has a platelet count \ 700,000 cells/mm3. * known non-adherence to double anti-platelet therapy (dapt) * lvef \<30% * continuing bleeding * acute coronary syndrome (st-elevation myocardial infarction) * pregnancy

Keywords: percutaneous coronary intervention coronary artery disease wire coronary stenting
effects of lactobacillus plantarum ps128 in patients with tourette's syndrome

Conditions: Tourette's Syndrome

Summary: to evaluate whether supplementing with ps128 can improve the symptoms and quality of life related to tourette's disease in children.

this is a randomized double-blind healthy control study and the implementation period is after institutional review board (irb) approval to december 31, 2022. experimental group: 80 subjects who meet the criteria for the admission of tourette's disease will be enrolled. they will consume the ps128 or placebo capsules every day, 2 capsules at a time, for 12 weeks. healthy control group: 40 subjects of the same age as the experimental group will be included, without any intervention measures, only collect stool sample once.

Eligibility criteria:
inclusion criteria: * age 4-18 years old * tourette's disease is diagnosed * make sure it is not caused by medication or other diseases * cause major interference in social interaction, study or work * the healthy control group is not diagnosed with tourette's disease, and is judged by pi exclusion criteria: * have taken antibiotics within a month or are receiving antibiotic treatment * used probiotic products in powder, capsule or tablet form within two weeks (except yogurt, yogurt, yakult and other related foods) * patients who have undergone hepatobiliary gastrointestinal surgery (except for colorectal polypectomy and appendectomy) * inflammatory bowel disease, such as crohn's disease or ulcerative colitis * those with a history of cancer * those who are allergic to lactic acid bacteria products * those who are not suitable to participate judged by pi